Ayala Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Roni Mamluk
- Full Time Employees
- 35
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4 Oppenheimer Street Rehovot Israel 7670104
- IPO Date
- May 8, 2020
- CIK
- 0001797336
- Website
- ayalapharma.com
- Similar Companies
- Business
- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) is a clinical-stage oncology company focused on developing targeted therapies for genetically defined cancers with significant unmet needs. The company offers a pipeline of product candidates including AL102, a gamma secretase inhibitor for desmoid tumors and recurrent T-cell acute lymphoblastic leukemia/lymphoma; AY130, an EZH2 inhibitor for B-cell lymphomas and other solid tumors; and AYP2001, a RASP1 inhibitor targeting pan-RAS mutant cancers, among other investigational therapies targeting Notch, EZH2, and RAS pathways. These products are advanced through preclinical and clinical development stages, with emphasis on precision oncology for rare and aggressive malignancies. [ from prior][ from prior] Founded in 2016 and headquartered in Boston, Massachusetts, Ayala Pharmaceuticals operates primarily in the United States with clinical trials conducted globally, targeting patients in oncology centers and academic institutions worldwide. The company serves pharmaceutical partners, healthcare providers, and patients through collaborative research and development efforts in the biopharmaceutical sector. Its business segments concentrate on small molecule inhibitors for specific genetic mutations prevalent in hard-to-treat cancers. In recent developments within the last 1-2 years, Ayala Pharmaceuticals completed a strategic merger with Cerecor Inc. in April 2023, which expanded its pipeline by adding CYP11D1 and KAT6 programs while transitioning leadership and refining its focus on rare cancer therapies. The company secured bridge financing of up to $12 million in 2024 to support ongoing operations and clinical advancements amid Nasdaq delisting challenges. Additionally, Ayala announced positive interim data from its Phase 2 AL102 study in desmoid tumors and continued enrollment in other trials, marking key progress in its precision medicine portfolio without major name changes or reorganizations. [ from prior][ from prior][ from prior]
Os Therapies Posts Wider Loss in Q2
AYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders
Ayala Pharmaceuticals, Inc. (AYLA) Upgraded to Buy: Here's Why
Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress
7 Short-Squeeze Stocks to Put on Your Must-Watch List
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Misses Revenue Estimates
Penny Stocks To Buy Now? 4 To Watch After LTRPB Stock Jumped Over 372%
Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates
Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
How Much Upside is Left in Ayala Pharmaceuticals, Inc. (AYLA)? Wall Street Analysts Think 116%
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Misses Revenue Estimates
Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference
Earnings Preview: Ayala Pharmaceuticals, Inc. (AYLA) Q3 Earnings Expected to Decline
Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Lags Revenue Estimates
Recap: Ayala Pharmaceuticals Q2 Earnings